Last synced on 23 May 2025 at 11:06 pm

Chronic Lymphocytic Leukemia Fish Probe Kit

Page Type
Product Code
Definition
The CLL FISH Probe Kit is intended to detect deletion of the LSI TP53, LSI ATM, and LSI D13S319 probe targets and gain of the D12Z3 sequence in peripheral blood specimens from untreated patients with B-cell chronic lymphocytic leukemia (CLL). The assay may be used to dichotomize CLL (the 13q-, +12, or normal genotype group versus the 11q- or 17p- group) and may be used as an aid in determining disease prognosis in combination with additional biomarkers, morphology and other clinical information.
Physical State
Reagents for B-cell chronic lymphocytic leukemia prognosis
Technical Method
Fluorescent in situ hybridization
Target Area
B-cell chronic lymphocytic leukemia
Regulation Medical Specialty
Immunology
Review Panel
Pathology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
866.6040
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Third Party Eligible

CFR § 866.6040 Gene expression profiling test system for breast cancer prognosis

§ 866.6040 Gene expression profiling test system for breast cancer prognosis.

(a) Identification. A gene expression profiling test system for breast cancer prognosis is a device that measures the ribonucleic acid (RNA) expression level of multiple genes and combines this information to yield a signature (pattern or classifier or index) to aid in prognosis of previously diagnosed breast cancer.

(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Gene Expression Profiling Test System for Breast Cancer Prognosis.” See § 866.1(e) for the availability of this guidance document.

[72 FR 26291, May 9, 2007]

Chronic Lymphocytic Leukemia Fish Probe Kit

Page Type
Product Code
Definition
The CLL FISH Probe Kit is intended to detect deletion of the LSI TP53, LSI ATM, and LSI D13S319 probe targets and gain of the D12Z3 sequence in peripheral blood specimens from untreated patients with B-cell chronic lymphocytic leukemia (CLL). The assay may be used to dichotomize CLL (the 13q-, +12, or normal genotype group versus the 11q- or 17p- group) and may be used as an aid in determining disease prognosis in combination with additional biomarkers, morphology and other clinical information.
Physical State
Reagents for B-cell chronic lymphocytic leukemia prognosis
Technical Method
Fluorescent in situ hybridization
Target Area
B-cell chronic lymphocytic leukemia
Regulation Medical Specialty
Immunology
Review Panel
Pathology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
866.6040
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Third Party Eligible

CFR § 866.6040 Gene expression profiling test system for breast cancer prognosis

§ 866.6040 Gene expression profiling test system for breast cancer prognosis.

(a) Identification. A gene expression profiling test system for breast cancer prognosis is a device that measures the ribonucleic acid (RNA) expression level of multiple genes and combines this information to yield a signature (pattern or classifier or index) to aid in prognosis of previously diagnosed breast cancer.

(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Gene Expression Profiling Test System for Breast Cancer Prognosis.” See § 866.1(e) for the availability of this guidance document.

[72 FR 26291, May 9, 2007]